Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Stock Purchase Agreements (Narrative) (Details)

v3.21.1
Collaboration and Stock Purchase Agreements (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
3 Months Ended
Feb. 24, 2021
Feb. 08, 2019
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Cash and cash equivalents     $ 289,897   $ 233,351
Collaboration revenue     800 $ 0  
Accumulated deficit     (491,582)   $ (482,760)
Cyprium [Member] | Sentynl Therapeutics, Inc [Member]          
Upfront fees payment $ 8,000        
Payments of milestones $ 12,000        
Percentage of ownership over any FDA priority review voucher 100.00%        
Collaboration revenue     800 $ 0  
Avenue [Member]          
Cash and cash equivalents     1,800    
Accumulated deficit     (74,300)    
SPMA [Member] | Avenue [Member] | InvaGen [Member]          
Business Combination, possible Interim financing, amount drawn     0    
SPMA [Member] | Minimum [Member] | Avenue [Member] | InvaGen [Member]          
Percentage of common shares acquired in the Stock Purchase Transaction for the rights to exist   75.00%      
SPMA [Member] | Maximum [Member] | Avenue [Member] | InvaGen [Member]          
Business Combination, possible Interim financing   $ 7,000      
FDA approval of the NDA [Member] | Cyprium [Member] | Sentynl Therapeutics, Inc [Member]          
Payments of milestones $ 9,000        
Achievement of Certain Sales Milestones [Member] | Cyprium [Member] | Sentynl Therapeutics, Inc [Member]          
Payments of milestones 255,000        
Strategic Transaction, First Stage [Member] | SPMA [Member] | Avenue [Member] | InvaGen [Member]          
Sale of stock, number of shares issued   5.8      
Sale of stock, price per share   $ 6.00      
Sale of Stock, Consideration Received on Transaction   $ 35,000      
Sale of stock, ownership percentage after the transaction   33.30%      
Strategic Transaction, Second Stage [Member] | SPMA [Member] | Avenue [Member] | InvaGen [Member]          
Sale of Stock, Consideration Received on Transaction   $ 180,000      
Completion of Clinical Development Milestones [Member] | Cyprium [Member] | Sentynl Therapeutics, Inc [Member]          
Payments of milestones $ 3,000        
IV Tramadol [Member] | FDA approval of the NDA [Member] | Avenue [Member]          
Payments of milestones     $ 5,000